-- Seres Group (SHA:601127, HKG:9927) sold 35,461 vehicles in April, down 0.8% from a year earlier.
Output for the month slipped 4.2% year over year to 37,167 units, the vehicle maker said Tuesday in a Hong Kong bourse filing.
For the four months ended April 30, group sales and output were up 19% and 15.4%, respectively, to 123,906 vehicles and 123,876 units.
Troilus Mining (TLG.TO) increased its previously announced debt financing mandate from up to US$1.0 billion to up to US$1.2 billion.The upsizing reflects "continued strong lender support and advancing progress toward a fully funded construction package for the Troilus copper-gold project, located in north-central Quebec, Canada," it said.The financing is being led by a syndicate of leading global financial institutions, including Societe Generale, KfW IPEX-Bank, and Export Development Canada, and is expected to form the cornerstone of the project's overall financing structure, the company added.Shares of the company closed down 1.2% to $1.59 on Monday on the Toronto Stock Exchange.
IPG Photonics (IPGP) reported Q1 adjusted earnings Tuesday of $0.29 per diluted share, down from $0.31 a year earlier.An analyst polled by FactSet expected $0.31.Revenue for the quarter ended March 31 was $265.5 million, compared with $227.8 million a year earlier.An analyst polled by FactSet expected $265.5 million.The company expects Q2 adjusted EPS of $0.25 to $0.55 and $260 million to $290 million in revenue. Analysts polled by FactSet expect $0.44 in adjusted EPS on revenue of $275.7 million.Separately, IPG Photonics said it agreed on a global settlement with TRUMPF Laser- und Systemtechnik to resolve and close their patent dispute. No other details were disclosed.Shares of IPG Photonics were down more than 17% premarket Tuesday.Price: $100.60, Change: $-21.73, Percent Change: -17.76%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:IDEXX posted strong Q1 results with EPS of $3.47 (+17% Y/Y), beating expectations by $0.06, while revenue reached $1.141B (+14% Y/Y), $30M above consensus. CAG Diagnostics recurring revenue grew 14% Y/Y to $920M, demonstrating resilient demand for core diagnostic solutions. Operating margin expanded 10 bps to 31.8%, supported by strong recurring revenue gains and operational productivity initiatives. International markets showed particular strength with CAG revenue growing 22.7% compared to 11% domestically, highlighting successful global expansion efforts, in our view. The 12% expansion in the global premium instrument installed base and 20% growth in VetLab consumables underscore continued innovation adoption. Management raised the full-year 2026 guidance, reflecting confidence in the business trajectory, in our view: IDXX sees 2026 sales in the range of $4.675B-4.760B vs. prior $4.632B-$4.720B, representing +8.6%-10.6% Y/Y growth and EPS of $14.45-$14.90 vs. prior $14.29-$14.80, reflecting +11%-14% Y/Y.